Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$1.1M
Filings
14
Firms Hired
1
Active Period
2017–2019
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Stop Tampering of Prescription Pills Act of 2015
2018 · third_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Client expense: $164,000 · Firm income: —
Matched citations: H.R. 2335
Curb Opioid Misuse By Advancing Technology Act of 2016
2018 · third_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Client expense: $164,000 · Firm income: —
Matched citations: H.R. 5127
Opioid Abuse Deterrence, Research, and Recovery Act of 2017
2018 · third_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Client expense: $164,000 · Firm income: —
Matched citations: H.R. 4482
Abuse Deterrent Access Act of 2018
2018 · third_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare H.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Client expense: $164,000 · Firm income: —
Matched citations: H.R. 5582
Comprehensive Addiction and Recovery Act of 2016
2018 · third_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Client expense: $164,000 · Firm income: —
Matched citations: S. 524
Substance Abuse Prevention Act of 2018
2018 · third_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Client expense: $164,000 · Firm income: —
Matched citations: S. 2789
Substance Abuse Prevention Act of 2018
2018 · third_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare H.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Client expense: $164,000 · Firm income: —
Matched citations: S. 2789
Stop Tampering of Prescription Pills Act of 2015
2018 · second_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Client expense: $147,000 · Firm income: —
Matched citations: H.R. 2335
Curb Opioid Misuse By Advancing Technology Act of 2016
2018 · second_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Client expense: $147,000 · Firm income: —
Matched citations: H.R. 5127
Opioid Abuse Deterrence, Research, and Recovery Act of 2017
2018 · second_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Client expense: $147,000 · Firm income: —
Matched citations: H.R. 4482
Abuse Deterrent Access Act of 2018
2018 · second_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare H.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Client expense: $147,000 · Firm income: —
Matched citations: H.R. 5582
Comprehensive Addiction and Recovery Act of 2016
2018 · second_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Client expense: $147,000 · Firm income: —
Matched citations: S. 524
Substance Abuse Prevention Act of 2018
2018 · second_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Client expense: $147,000 · Firm income: —
Matched citations: S. 2789
Substance Abuse Prevention Act of 2018
2018 · second_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare H.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Client expense: $147,000 · Firm income: —
Matched citations: S. 2789
Stop Tampering of Prescription Pills Act of 2015
2018 · first_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues
Client expense: $178,000 · Firm income: —
Matched citations: H.R. 2335
Curb Opioid Misuse By Advancing Technology Act of 2016
2018 · first_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues
Client expense: $178,000 · Firm income: —
Matched citations: H.R. 5127
Opioid Abuse Deterrence, Research, and Recovery Act of 2017
2018 · first_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues
Client expense: $178,000 · Firm income: —
Matched citations: H.R. 4482
Comprehensive Addiction and Recovery Act of 2016
2018 · first_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Client expense: $178,000 · Firm income: —
Matched citations: S. 524
Stop Tampering of Prescription Pills Act of 2015
2017 · fourth_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues
Client expense: $143,000 · Firm income: —
Matched citations: H.R. 2335
Comprehensive Addiction and Recovery Act of 2016
2017 · fourth_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Client expense: $143,000 · Firm income: —
Matched citations: S. 524
Stop Tampering of Prescription Pills Act of 2015
2017 · third_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Client expense: $143,000 · Firm income: —
Matched citations: H.R. 2335
Comprehensive Addiction and Recovery Act of 2016
2017 · third_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Client expense: $143,000 · Firm income: —
Matched citations: S. 524
Opioid Addiction Risk Transparency Act
2017 · third_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Client expense: $143,000 · Firm income: —
Matched citations: S. 1049
Stop Tampering of Prescription Pills Act of 2015
2017 · second_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids H.R. 2430, provisions related to the reauthorization of the Prescription Drug User Fee Act 1st Amendment/Communications with payors/off-label policy issues Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Client expense: $180,000 · Firm income: —
Matched citations: H.R. 2335
Curb Opioid Misuse By Advancing Technology Act of 2016
2017 · second_quarter · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids H.R. 2430, provisions related to the reauthorization of the Prescription Drug User Fee Act 1st Amendment/Communications with payors/off-label policy issues Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Client expense: $180,000 · Firm income: —
Matched citations: H.R. 5127
Source: Senate LDA